Brookings Roundtable on Active Medical Product Surveillance: Learning from the Observational Medical Outcomes Partnership (OMOP)
On July 1, the Engelberg Center for Health Care Reform hosted the roundtable webinar, “Learning from the Observational Medical Outcomes Partnership (OMOP).”
Download presentation slides » (pdf)
Discussion featured presentations from Patrick Ryan, Manager, Drug Development Sciences, GlaxoSmithKline Research and Development and Co-Investigator, Observational Medical Outcomes Partnership; and Dr. David Madigan, Professor and Chair of Statistics, Columbia University and Research Investigator, Observational Medical Outcomes Partnership.
Presentations focused on OMOP’s research into observational methods for analyzing existing health care databases to evaluate the safety and benefit of drugs already on the market, as well as the results of the recent methods competition, the OMOP Cup. Mr. Ryan provided an overview of the OMOP methods program, and Dr. Madigan discussed the simulated data set that was used for the competition, the prize-winning methods, implications for active medical product surveillance, and ideas for future methods work.
Welcome and Introduction
Mark B. McClellan
Former Brookings Expert
Director, Margolis Center for Health Policy - Duke University
OMOP Methods Program
OMOP Methods Cup and its Relevance to Active Surveillance
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.